Home » Stocks » Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc. (IONS)

Stock Price: $53.09 USD 0.11 (0.21%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed
After-hours: $53.10 +0.01 (0.02%) Aug 13, 5:51 PM

Stock Price Chart

Key Info

Market Cap 7.42B
Revenue (ttm) 940.48M
Net Income (ttm) 130.51M
Shares Out 139.70M
EPS (ttm) 0.92
PE Ratio 57.71
Forward PE 70.42
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $53.09
Previous Close $52.98
Change ($) 0.11
Change (%) 0.21%
Day's Open 52.98
Day's Range 52.41 - 53.44
Day's Volume 486,894
52-Week Range 39.32 - 73.09

More Stats

Market Cap 7.42B
Enterprise Value 5.88B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 139.70M
Float 132.68M
EPS (basic) 0.92
EPS (diluted) 0.92
FCF / Share 1.23
Dividend n/a
Dividend Yield n/a
Earnings Yield 1.73%
FCF Yield 2.31%
Payout Ratio n/a
Shares Short 8.63M
Short Ratio 12.46
Short % of Float 6.93%
Beta 1.60
PE Ratio 57.71
Forward PE 70.42
P/FCF Ratio 43.23
PS Ratio 7.89
PB Ratio 5.37
Revenue 940.48M
Operating Income 150.30M
Net Income 130.51M
Free Cash Flow 171.56M
Net Cash 1.54B
Net Cash / Share 11.02
Gross Margin 69.62%
Operating Margin 15.98%
Profit Margin 13.90%
FCF Margin 18.24%
ROA 3.20%
ROE 7.87%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (21)

Buy 9
Overweight 1
Hold 7
Underweight 0
Sell 4

Analyst Consensus: Overweight

Price Target

(27.78% upside)
Current: $53.09
Target: 67.84
*Average 12-month price target from 19 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth87.2%16.63%37.93%31.4%32.47%45.41%44.33%2.99%-8.65%-
Gross Profit1,11859851437328421414710299.09108
Operating Income366-61.3731.05-20.16-75.76-47.73-51.67-68.92-71.10-48.36
Net Income2942740.35-60.40-88.28-38.98-60.64-65.48-84.80-61.25
Shares Outstanding14013212412112011811110199.6699.14
Earnings Per Share2.082.070.15-0.50-0.74-0.33-0.55-0.65-0.85-0.62
EPS Growth0.48%1280%--------
Operating Cash Flow346603174-11221.136.2963.491.88-112-63.59
Capital Expenditures-30.91-13.61-34.76-7.11-7.69-7.52-1.55-1.48-10.20-2.91
Free Cash Flow315589139-11913.43-1.2361.940.40-122-66.50
Cash & Equivalents2,5002,0841,023665804811709408344472
Total Debt788647607589473458233227223155
Net Cash / Debt1,7121,43741576.12331353476181120317
Book Value1,4711,04828199.57201258378183171245
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Ionis Pharmaceuticals, Inc.
Country United States
Employees 817
CEO Brett P. Monia

Stock Information

Ticker Symbol IONS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: IONS
IPO Date May 17, 1991


Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic from ALS; ION859 for Parkinson's disease; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing severe and rare disease products, such as AKCEA-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-PKK-LRx for hereditary angioedema; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-ENAC-2.5Rx for cystic fibrosis; and ION357 for retinitis pigmentosa. In addition, its cardio metabolic and renal drugs include AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular diseases; AKCEA-ANGPTL3-LRx for cardio metabolic disorders; IONIS-GCGRRx for type 2 diabetes; IONIS-AGT-LRX for the treatment of resistant hyper tension; IONIS-FXI-LRx for clotting disorders; IONIS-AZ4-2.5-LRx for cardiovascular diseases; and ION839 for nonalcoholic steatohepatitis. Further, the company develops products for oncology that include IONIS-AR-2.5Rx and danvatirsen for cancers; IONIS-HBVRx and IONIS-HBV-LRx for hepatitis B virus infection; and IONIS-FB-LRx for compliment meditated disease. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.